RT Journal Article
SR Electronic
T1 A new class of drugs for systolic heart failure: The PARADIGM-HF study
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 693
OP 701
DO 10.3949/ccjm.82a.14163
VO 82
IS 10
A1 Marwa A. Sabe
A1 Miriam S. Jacob
A1 David O. Taylor
YR 2015
UL http://www.ccjm.org/content/82/10/693.abstract
AB The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.